Release – 1-800-FLOWERS.COM, Inc. Advances Its Customer Engagement Strategy

Posted on January 11, 2022 by Admin

1-800-FLOWERS.COM, Inc. Advances Its Customer Engagement Strategy and Ongoing Focus on Embracing Entrepreneurs with Acquisition of Alice’s Table®

Research, News, and Market Data on 1-800-FLOWERS.COM

Company Further Expands Experiential Offerings with Broad Range of Interactive Livestreaming Events for Public, Private, and Corporate Guests Across the Country

JERICHO, N.Y.–(BUSINESS WIRE)– Today, 1-800-FLOWERS.COM, Inc. (NASDAQ: FLWS) (“the Company”), a leading provider of gifts designed to help customers express, connect, and celebrate, announced it has expanded its experiential offerings with the acquisition of Alice’s Table®, a lifestyle business offering fully digital and highly curated livestreaming floral, culinary, and other unique experiences to public event guests, as well as to private and corporate clients across the country. This expansion reflects the Company’s strategic focus on developing immersive experiences, engaging content, and interactive events, as well as embracing entrepreneurial concepts that help deepen relationships with customers and create a real sense of community.

Launched in 2015 by Alice Lewis, Alice’s Table began by hosting in-person floral arranging events in homes and venues throughout the
U.S. It pivoted to a purely digital model in 2020, when it began collaborating with 1-800-Flowers.com® and Harry & David® to scale experiences in order to provide memorable interactive events, such as designing floral arrangements and creating charcuterie boards, to a broader audience of both large and small groups.

“In our continuous efforts to inspire more human expression, connection, and celebration, 1-800-FLOWERS.COM, Inc. is always looking to see what the entrepreneurial community is developing that will bring inspiration to our world,” said Dinesh Popat, President, BloomNet®. “Our collaboration with Alice’s Table began right at the beginning of the pandemic, and since then it has given more than 80,000 people the opportunity to celebrate their creative capabilities – and have some fun! Alice and her team’s passion for bringing customers unforgettable events aligns perfectly with our company’s vision. As we move forward, our focus will be on developing additional experiential concepts with Alice’s Table, creating even more exciting new ways for customers to engage with our family of brands — and with each other.”

“I am so proud of this tremendous moment of growth for the Alice’s Table brand,” says Alice Lewis, who will remain with the company as President, Alice’s Table. “The 1-800-FLOWERS.COM, Inc. team has given us such incredible support over the past two years in helping us bring best-in-class virtual experiences to people coast-to-coast. This next phase in our relationship will allow us to expand our reach to millions of new customers and to deliver more of the next generation experiences our guests have come to love.”

Since its inception, Alice’s Table has offered thousands of interactive events that mix top instructor talent with crave-worthy DIY kits to provide fun-filled experiences for connecting with friends, family, and co-workers. These include special celebratory moments, such as bridal showers and birthday parties, corporate team building, and more. Currently, Alice’s Table offers approximately 10 unique step-by-step workshop themes for public event guests to choose from each month, with new themes designed and introduced seasonally, keeping the offerings fresh, exciting, and on trend.

For downloadable images, please visit the 1-800-FLOWERS.COM, Inc. Newsroom.

About 1-800-FLOWERS.COM, Inc.
1-800-FLOWERS.COM, Inc. is a leading provider of gifts designed to help customers express, connect and celebrate. The Company’s e-commerce business platform features an all-star family of brands, including: 1-800-Flowers.com®, 1-800-Baskets.com®, Cheryl’s Cookies®, Harry & David®, PersonalizationMall.com®, Shari’s Berries®, FruitBouquets.com®, Moose Munch®, The Popcorn Factory®, Wolferman’s Bakery®, Vital Choice®,
Stock Yards® and Simply Chocolate®. Through the Celebrations Passport® loyalty program, which provides members with free standard shipping and no service charge across our portfolio of brands, 1-800-FLOWERS.COM, Inc. strives to deepen relationships with customers. The Company also operates BloomNet®, an international floral and gift industry service provider offering a broad-range of products and services designed to help members grow their businesses profitably; Napco?, a resource for floral gifts and seasonal décor; and DesignPac Gifts, LLC, a manufacturer of gift baskets and towers. 1-800-FLOWERS.COM, Inc. was recognized among the top 5 on the National Retail Federation’s 2021 Hot 25 Retailers list, which ranks the nation’s fastest-growing retail companies. Shares in 1-800-FLOWERS.COM, Inc. are traded on the NASDAQ Global Select Market, ticker symbol: FLWS. For more information, visit 1800flowersinc.com or follow @1800FLOWERSInc on Twitter.

FLWS-COMP
FLWS-FN
FLWS-AT

Investor:

Joseph D. Pititto

(516) 237-6131

invest@1800flowers.com

Media:

Kathleen Waugh

(516) 237-6028

kwaugh@1800flowers.com

Source: 1-800-FLOWERS.COM, Inc.

Release – Palladium One Intersects Widest Intercept to Date Southwest of the Kaukua Open Pit Resource Estimate Finland

Posted on January 11, 2022 by Admin

Palladium One Intersects Widest Intercept to Date Southwest of the Kaukua Open Pit Resource Estimate, Finland, 1.6 g/t Pd_Eq over 121 Meters

Research, News, and Market Data on Palladium One Mining

Widest ore grade intercept to date, intersected 250 meters southwest and down plunge of the current Kaukua Open Pit Mineral Resource Estimate (“MRE”).
2.1 g/t Palladium Equivalent (Pd_Eq) over 33.5 meters, within 1.6 g/t Pd_Eq over 121.1 meters, in hole LK21-105, with individual samples grading up to 16.0 g/t Pd_Eq over 0.6 meters.
Three holes (LK21-101, 102 and 105), spread over 220-meters laterally, have all intersected the down plunge, high-grade ‘Core Zone’ of the current pit constrained Kaukua Open Pit.
High-grade ‘Core Zone’ of the Kaukua Open Pit remains open to depth.

January 11, 2021 – Toronto, Ontario, Initial down plunge drilling, has intersected the widest ore-grade intercept to date, southwest of the 2019 open-pit constrained MRE of the Kaukua Deposit. Hole LK21-105 intersected 2.1 g/t Pd_Eq over 33.5 meters, within 1.6 g/t Pd_Eq over 121.1 meters, starting at a true depth of approximately 260 meters (Figure 2), said Palladium One Mining Inc. (“Palladium One” or the “Company”).

Derrick Weyrauch, President and CEO commented: “We have extended the ‘Core Zone’ of the Kaukua Deposit 250 beyond the current conceptual open-pit and hole LK21-105 is among the thickest intercepts to date within the Kaukua Deposit and adds significant tonnage to our existing resource endowment. The high-grade ‘Core Zone’ of the Kaukua Deposit remains open to the southwest for more expansion. An updated NI43-101 Mineral Resource Estimate is schedule for release in Q1 2022 and will incorporate these valuable results”

These drilling results extend a broad, >200-meter wide ‘core zone’ of mineralization 250-meters southwest of the existing conceptual open-pit, and it remains open for expansion (Figure 1 and 2, and 3). Importantly, the previous geological interpretations suggested that the Kaukua Deposit was cut-off by a northwest trending fault, occupying a distinct magnetic low and topographic lineament. Drilling has now demonstrated that the magnetic low is the result of a later cross cutting dyke (now referred to as the high-titanium gabbro dyke) and that the Kaukua Deposit remains open to the south. Significantly the high-grade ‘Core Zone’ of the Kaukua Deposit has been extended 250 meters to the southwest and we have encountered some of the thickest intercepts (>100m) to date within the deposit (see news release November 23, 2021).

Figure 1. Historic and current drilling in the Kaukua area having a drill data cut-off date of September 30, 2021 (hole LK21-137), assays have been received for holes up to LK21-108, the remainder are pending. Background is Induced Polarization (“IP”) Chargeability.

Figure 2. Cross sections showing holes LK21-099, 103, 104, 105 and 106 and historic holes KAU09-049 and KAU12-060, and their position with respect to the 2019 Kaukua Mineral Resource Estimate Whittle Open Pit.

Figure 3. Cross section showing holes LK21-100, 108, historic holes KAU09–040, 042, 043, KAU12-053 and their position with respect to the 2019 Kaukua Whittle Open-Pit constrained Mineral Resource Estimate.

Table 1. LK Project, select Kaukua Drill Hole Results

Hole

From
(m)

To
(m)

Width
(m)

Pd_Eq g/t*
In-Situ

Pd_Eq g/t*
Estimated Recovered

PGE
(Pt+Pd+Au)

Pd
g/t

Pt
g/t

Au
g/t

Cu
%

Ni
%

Co
g/t

LK21-100
Upper Zone

37.6

64.0

26.4

0.67

0.42

0.16

0.09

0.03

0.04

0.09

0.10

Inc.

37.6

42.0

4.4

1.03

0.67

0.38

0.21

0.09

0.07

0.14

0.13

Lower Zone

246.2

359.5

113.4

1.46

0.93

0.87

0.61

0.21

0.04

0.09

0.14

Inc.

246.2

284.5

38.4

2.03

1.33

1.30

0.91

0.32

0.07

0.14

0.17

Inc.

249.5

259.0

9.6

3.27

2.21

2.25

1.54

0.54

0.17

0.27

0.21

111

Inc.

249.5

254.0

4.6

4.02

2.71

2.82

1.94

0.68

0.21

0.30

0.26

121

And

330.8

338.0

7.2

2.99

2.03

2.31

1.69

0.53

0.08

0.18

0.16

Inc.

330.8

335.0

4.2

3.98

2.71

3.20

2.35

0.75

0.10

0.21

0.19

Inc.

330.8

332.0

1.2

5.65

3.85

4.65

3.50

1.01

0.14

0.25

132

And

351.0

359.5

8.5

2.73

1.81

1.87

1.31

0.49

0.07

0.19

0.20

105

Inc.

358.0

359.5

1.5

5.88

3.97

4.45

2.95

1.42

0.08

0.48

0.33

111

LK21-101
Upper Zone

83.0

100.8

17.8

0.76

0.45

0.15

0.08

0.03

0.04

0.08

0.13

103

Lower Zone

272.6

347.1

74.5

1.46

0.94

0.72

0.49

0.17

0.06

0.13

0.16

Inc.

276.9

298.7

21.8

1.68

1.08

0.92

0.61

0.23

0.08

0.13

0.17

Inc.

290.6

298.7

8.1

2.49

1.67

1.52

1.00

0.36

0.16

0.24

0.20

And

325.4

345.0

19.6

2.22

1.47

1.19

0.81

0.28

0.10

0.24

0.21

106

Inc.

325.4

334.0

8.6

2.70

1.84

1.65

1.13

0.38

0.13

0.30

0.20

Inc.

333.0

334.0

1.0

4.15

2.77

1.51

1.03

0.29

0.19

0.70

0.48

177

LK21-102
Upper Zone

62.8

82.5

19.7

0.68

0.42

0.16

0.09

0.03

0.04

0.09

0.10

Lower Zone

248.2

361.8

113.6

1.57

1.02

0.92

0.63

0.23

0.06

0.12

0.14

Inc.

291.5

361.8

70.3

1.85

1.22

1.15

0.80

0.29

0.07

0.15

Inc.

291.5

305.2

13.7

3.16

2.12

2.21

1.58

0.55

0.09

0.24

0.21

107

Inc.

296.0

299.0

3.0

4.22

2.79

3.07

2.22

0.77

0.08

0.21

0.30

141

And

348.7

361.8

13.1

3.04

2.04

2.03

1.39

0.51

0.12

0.26

0.21

104

Inc.

357.7

359.7

2.0

7.98

5.52

5.82

3.97

1.48

0.37

0.78

0.41

138

Inc.

358.7

359.7

1.0

9.56

6.64

7.08

4.81

1.83

0.44

0.95

0.46

150

LK21-103
Upper Zone

54.3

77.0

22.7

0.88

0.55

0.27

0.10

0.03

0.13

0.10

0.12

Inc.

55.9

62.0

6.2

1.23

0.84

0.57

0.13

0.05

0.38

0.15

0.12

Lower Zone

248.0

343.5

95.5

0.75

0.45

0.29

0.20

0.07

0.02

0.05

0.11

Inc.

258.0

330.5

72.5

0.84

0.50

0.31

0.21

0.08

0.02

0.05

0.13

Inc.

258.0

275.0

17.0

1.19

0.72

0.49

0.35

0.12

0.03

0.07

0.17

108

Inc.

272.0

273.5

1.5

3.12

2.11

2.01

1.42

0.46

0.13

0.29

0.22

128

And

319.8

330.5

10.7

1.27

0.83

0.82

0.57

0.20

0.04

0.09

0.10

Inc.

326.0

329.0

3.0

2.18

1.44

1.39

0.97

0.33

0.08

0.16

0.18

LK21-104
Upper Zone

15.3

43.0

27.8

0.81

0.51

0.18

0.10

0.03

0.06

0.12

Inc.

16.8

22.0

5.3

1.07

0.69

0.34

0.17

0.07

0.10

0.16

0.14

Lower Zone

209.5

278.0

68.5

0.75

0.42

0.20

0.14

0.05

0.01

0.03

0.14

Inc.

211.2

221.2

10.0

1.28

0.79

0.60

0.42

0.16

0.03

0.08

0.16

105

LK21-105
Upper Zone

120.4

131.1

10.8

0.86

0.53

0.20

0.11

0.03

0.06

0.11

0.13

Lower Zone

304.3

425.3

121.1

1.57

1.01

0.85

0.59

0.21

0.05

0.13

0.16

Inc

321.0

323.7

2.7

3.13

2.15

2.12

1.53

0.49

0.10

0.31

0.18

116

And

344.0

346.9

2.9

4.34

2.92

2.69

1.85

0.66

0.18

0.43

0.33

160

Inc.

346.0

346.9

0.9

7.78

5.29

5.18

3.58

1.25

0.35

0.75

0.52

206

And

390.8

424.3

33.5

2.07

1.36

1.19

0.82

0.29

0.08

0.18

0.19

Inc.

407.7

418.9

11.3

2.56

1.65

1.37

0.97

0.32

0.09

0.21

0.27

116

Inc.

407.7

408.2

0.6

15.99

9.54

6.07

4.91

1.07

0.09

0.85

2.60

725

LK21-106
Upper Zone

123.1

137.9

14.8

0.95

0.56

0.20

0.12

0.03

0.05

0.09

0.16

119

Inc.

129.0

130.5

1.5

1.50

0.94

0.43

0.26

0.06

0.12

0.17

0.22

138

Lower Zone

271.3

301.5

30.2

0.84

0.51

0.34

0.22

0.09

0.03

0.05

0.12

Inc.

271.3

277.0

5.7

1.34

0.82

0.59

0.40

0.16

0.03

0.10

0.17

119

LK21-107
Upper Zone

86.3

107.0

20.7

0.70

0.42

0.14

0.08

0.03

0.04

0.09

0.11

Inc.

89.0

90.0

1.0

1.22

0.80

0.45

0.24

0.12

0.10

0.19

0.14

Lower Zone

253.5

262.6

9.1

0.77

0.53

0.17

0.12

0.05

0.01

0.19

0.08

Inc.

261.7

262.6

0.9

3.16

2.71

0.03

0.00

0.03

1.84

0.08

120

LK21-108
Upper Zone

55.7

87.0

31.3

0.59

0.36

0.12

0.06

0.02

0.03

0.08

0.09

Inc.

77.2

79.3

2.1

1.15

0.78

0.24

0.12

0.03

0.08

0.26

0.14

Lower Zone

264.0

345.9

81.9

0.86

0.51

0.32

0.21

0.07

0.03

0.05

0.13

Inc.

265.5

277.2

11.7

1.21

0.73

0.56

0.41

0.13

0.03

0.05

0.16

106

And

336.0

345.9

9.9

2.03

1.34

1.24

0.84

0.29

0.11

0.16

0.17

103

Inc.

337.7

341.0

3.3

3.57

2.44

1.69

0.58

0.17

0.33

0.22

108

* Pd_Eq calculated using in-situ values and prices from the 2021 NI43-101 Haukiaho Mineral Resource Estimate; $1,600/oz Pd, $1,100/oz Pt, $1,650/oz Au, $3.50 Cu, and $7.50/lb Ni, and $20/lb Co. Limited historical metallurgical work on the Kaukua Deposit indicates final recoveries in the range of 73% Pd, 56% Pt, 78% Au, 91% Cu, 48% Ni and 48% Co and are used in the Estimated Recovered Pd_Eq grade calculation.
**Italicised orange highlighted results are previously released results see news release November 23, 2021.

Palladium Equivalent
The Company is calculating Palladium equivalent using US$1,600 per ounce for palladium, US$1,100 per ounce for platinum, US$1,650 per ounce for gold, US$3.50 per pound for copper, US$7.50 per pound for nickel, and $20 per pound cobalt consistent with the calculation used in the Company’s September 2021 NI 43-101 Haukiaho Resource Estimate.

Qualified Person
The technical information in this release has been reviewed and verified by Neil Pettigrew, M.Sc., P. Geo., Vice President of Exploration and a director of the Company and the Qualified Person as defined by National Instrument 43-101

About Palladium One
Palladium One Mining Inc. (TSXV: PDM) is focused on discovering environmentally and socially conscious Metals for Green Transportation. A Canadian mineral exploration and development company, Palladium One is targeting district scale, platinum-group-element (PGE)-copper-nickel deposits in leading mining jurisdictions. Its flagship project is the Läntinen Koillismaa (LK) Project in north-central Finland, which is ranked by the Fraser Institute as one of the world’s top countries for mineral exploration and development. LK is a PGE-copper-nickel project that has existing Mineral Resources. PDM’s second project is the 2020 Discovery of the Year Award winning Tyko Project, a high-grade sulphide, copper-nickel project located in Canada. Follow Palladium One on LinkedIn, Twitter, and at www.palladiumoneinc.com.

ON BEHALF OF THE BOARD
“Derrick Weyrauch”
President & CEO, Director

For further information contact:
Derrick Weyrauch, President & CEO
Email: info@palladiumoneinc.com

Neither the TSX Venture Exchange nor its Market Regulator (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release is not an offer or a solicitation of an offer of securities for sale in the United States of America. The common shares of Palladium One Mining Inc. have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration.

Information set forth in this press release may contain forward-looking statements. Forward-looking statements are statements that relate to future, not past events. In this context, forward-looking statements often address a company’s expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with project development; the need for additional financing; operational risks associated with mining and mineral processing; fluctuations in palladium and other commodity prices; title matters; environmental liability claims and insurance; reliance on key personnel; the absence of dividends; competition; dilution; the volatility of our common share price and volume; and tax consequences to Canadian and U.S. Shareholders. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements.

Release – Chakana Reports Initial Inferred Resource on Seven Breccia Pipes at the Soledad Project Peru

Posted on January 11, 2022 by Admin

Chakana Reports Initial Inferred Resource on Seven Breccia Pipes at the Soledad Project, Peru

Research, News, and Market Data on Chakana Copper

Soledad Project Highlights Include:

Inferred Resources were estimated for seven breccia pipes that start at surface and extend to an average depth of approximately 300 metres; all zones remain open at depth

Inferred Resources of 4.8 million tonnes grading 0.72 g/t gold, 61 g/t silver and 0.97% copper assumed to be extractable by underground mining methods

Inferred Resources of 1.9 million tonnes grading 1.29 g/t gold, 37.1 g/t silver and 0.65% copper assumed to be extractable by open pit mining methods

Opportunities for increasing the Inferred Resources include drill testing numerous additional breccia pipes identified on the property and extending the known mineralized zones at depth from the current Inferred Resources

16 out of 110 (15%) current targets have been tested to date, seven of which are included in the initial Inferred Resource estimate; several of the tested targets not included in the initial Inferred Resource estimate are mineralized and require additional exploration drilling

Vancouver, B.C., January 11, 2022 – Chakana Copper Corp. (TSX-V: PERU; OTCQB: CHKKF; FRA: 1ZX) (the “Company” or “Chakana”), is pleased to provide an initial Inferred Resource estimate for the Soledad Project, located in Ancash, Peru. Copper-gold-silver mineralization at the Soledad project is hosted within multiple, vertically-extensive tourmaline breccia pipes; important minerals are chalcopyrite, gold, electrum, and tetrahedrite.

The resource estimate confirms that the tourmaline breccia pipes at Soledad host significant mineralization with good continuity that is vertically extensive. The pipes exhibit strong zonation between gold, copper, and silver (Fig. 1). Drilling has confirmed the existence of blind breccia pipes that do not crop out a surface (Bx 1 North Zone), and breccia pipes that do crop out coalescing into larger breccias at depth (Huancarama East). The resource model, when combined with our other exploration data sets, helps refine the targeting model that will be used in future exploration drilling campaigns.

“We are very pleased to report the initial Inferred Resource estimate for the first seven breccia pipes, confirming that the Soledad pipes are attractive targets with good grades potentially amenable to both starter pits and underground mining methods. This initial Inferred Resource is particularly valuable for assessing the broader discovery potential of the project. So far, we have only drill tested 16 out of the 110 targets originally defined back in 2019, leading to seven of those targets being included in the initial resource estimate and several other mineralized targets identified. In addition to this, the recently completed Gradient Array and ongoing Offset IP surveys have identified numerous new targets that are being incorporated into our target inventory and ranked with the original targets. We have a large number of targets ready to test on the fully permitted north-half of the project where the initial resource estimate is located, and numerous additional targets on the south half of the project, including the Compañero breccia pipe complex. Drill permitting on the south-half of the project area is advancing with the efforts of our permitting team,” stated President and CEO David Kelley.

Since the commencement of its exploration at Soledad in 2017, Chakana has completed 260 core holes totaling 60,850m. The majority of the resource drilling was focused on Breccia Pipe 1 (Bx 1), Bx 5, Paloma East, and the eastern side of the Huancarama breccia complex, with much less drilling on Bx 6, Bx 7 and Paloma West. All zones are open to extension at depth, while many more targets remain untested in the broader Soledad project. Soledad is held under three separate 100% earn-in agreements with Condor Resources Inc, a private Peruvian company, and Barrick-Peru. The resources reported herein occur within a portion of the Condor and private Peruvian concessions.

Mineral resources were estimated by W.F. Tanaka (FAusIMM) and audited and accepted by Dr. Gilles Arseneau (PGeo.) of ARSENEAU Consulting Services Inc. of Vancouver. Resources were estimated for seven tourmaline breccias by ordinary kriging into 5 by 5 by 10 m blocks. Grades were composited to 5 m length and silver composites were capped at 500 g/t for Breccia 1 and 720 g/t for Breccia 6.

The mineral resources were estimated in accordance with the CIM Definition Standards on Mineral Resources and Mineral Reserves adopted by CIM Council, as amended, and in accordance with National Instrument 43-101. Near surface mineral resources were reported inside an optimized pit shell and at a dollar equivalent cut-off of US$ 25.00. The dollar equivalent is calculated using a US$1,600 per ounce for gold, US$20 per ounce for silver, and US$3.50 per pound for copper. Metallurgical recoveries were assumed to be 85% for gold, 75% for silver and 90% for copper. Material not captured by the optimized pit shell was assumed to be extractable by underground mining methods if the blocks were above a US$60 cut-off and represented a shape amenable to underground mining below the pit shell. Lead and zinc values also present at Soledad were not considered in the equivalent calculation.

Based on the above parameters, ACS estimated that the Soledad Project contains 4.8 million tonnes grading 0.72 g/t gold, 61 g/t silver and 0.97% copper amenable to extraction by underground mining methods plus an additional 1.9 million tonnes grading 1.29 g/t gold, 37.1 g/t silver and 0.65% copper amenable to extraction by open pit mining methods. All resources are classified as Inferred mineral resource as the term is defined by CIM. The QP is not aware of any known legal, political, environmental, or other risks that could materially affect the potential development of the mineral resources or mineral reserves per section 3.4(d) of 43-101.

Soledad Project – Inferred Mineral Resource Statement ACS, effective January 3, 2022

Cut -Off (US$)	Type	Breccia	Tonnes*	Au (g/t)	Ag (g/t)	Cu (%)
$25.00	Open Pit	Breccia 1	486,000	2.46	58.7	1.08
$25.00	Open Pit	Breccia 5	612,000	1.34	22.7	0.44
$25.00	Open Pit	Breccia 6	19,000	0.59	60.7	0.03
$25.00	Open Pit	Breccia 7	76,000	0.65	13.1	0.32
$25.00	Open Pit	Huancarama E	386,000	0.32	40.1	0.42
$25.00	Open Pit	Paloma E	141,000	0.61	18.2	0.35
$25.00	Open Pit	Paloma W	169,000	0.85	44.0	1.12
$25.00	Open Pit Total	All Pipes	1,889,000	1.29	37.1	0.65
$60.00	Underground	Breccia 1	2,170,000	0.65	85.7	1.24
$60.00	Underground	Breccia 5	1,045,000	1.08	13.6	0.86
$60.00	Underground	Breccia 6	114,000	1.28	88.5	0.29
$60.00	Underground	Breccia 7	177,000	0.78	103.7	0.11
$60.00	Underground	Huancarama E	1,185,000	0.52	53.5	0.79
$60.00	Underground	Paloma E	82,000	0.22	23.3	0.68
$60.00	Underground	Paloma W	67,000	0.59	17.0	0.78
$60.00	Underground Total	All Pipes	4,842,000	0.72	61.0	0.97

*Numbers may not add up exactly due to rounding

Qualified Persons

The Mineral Resource Estimate for the Soledad Project was prepared by Dr. Gilles Arseneau of Arseneau Consulting Services (ACS), an Independent Qualified Person (“QP”) as defined under NI 43-101, who has reviewed and approved the contents of this news release. The technical content of this news release has been reviewed and approved by David Kelley, an officer and a director of Chakana, and a Qualified Person as defined by NI 43-101– Standards of Disclosure of Mineral Projects. A technical report to support the Mineral Resource Estimate for the Soledad, prepared in accordance with NI 43-101, will be filed on SEDAR (www.sedar.com) within 45 days of the issuance of this news release.

Sampling and Analytical Procedures

All core is cut in half and sampled in one-metre intervals within a secured area until transport in batches to the ALS Chemex facility in Callao, Lima, Peru. Sample batches include certified reference materials, blank, and duplicate samples that are then processed under the control of ALS. All samples are analyzed using the ME-MS41 (ICP technique that provides a comprehensive multi-element overview of the rock geochemistry), while gold is analyzed by AA24 and GRA22 when values exceed 10 g/t by AA24. Over limit silver, copper, lead, and zinc are analyzed using the OG-46 procedure.

Results of previous drilling and additional information concerning the Project are available on Chakana’s SEDAR profile at www.sedar.com.

ON BEHALF OF THE BOARD

(signed) “David Kelley”
David Kelley
President and CEO

For further information contact:
Joanne Jobin, Investor Relations Officer
Phone: 647 964 0292
Email: jjobin@chakanacopper.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking Statement Advisory: This release may contain forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of Chakana to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Forward looking statements or information relates to, among other things, the interpretation of the nature of the mineralization at the Soledad copper-gold-silver project (the “Project”), the potential to expand the mineralization, and to develop and grow a resource within the Project, the planning for further exploration work, the ability to de-risk the potential exploration targets, and our belief in the potential for mineralization within unexplored parts of the Project. These forward-looking statements are based on management’s current expectations and beliefs but given the uncertainties, assumptions and risks, readers are cautioned not to place undue reliance on such forward- looking statements or information. The Company disclaims any obligation to update, or to publicly announce, any such statements, events or developments except as required by law.

Will Gold Continue to Outperform in 2022

Posted on January 11, 2022 by Admin



	Image Credit: Dennis Jarvis (Flickr)

Is Gold Still Preferred Over Large Digital Currencies as a Safe-Haven Asset?

Gold, it was said, has been replaced by cryptocurrencies like Ether (ETH) and Bitcoin (BTC) as the preferred safe-haven asset in times of uncertainty. This may very well come to be one day, but based on the upward movement of gold over the past three days of economic concern and stock market turmoil, and the downward movement of digital currencies, there are still many who will gravitate toward the hard asset.

As it has become clearer that the Fed will soon begin reacting more aggressively to reduce the easy money scenario that is playing into inflation’s strength, equity and interest rate markets have reacted as you’d expect them to; they sold off. There hasn’t been much of an opportunity, frankly, since Bitcoin’s founding to test its performance in the face of a fast ramp-up of interest rates. Although many factors impact price changes on any asset, it appears that gold futures prices are benefitting from the fears brought on after the December FOMC minutes became public on January 5th.

Dollar Weakness

The dollar has pulled back recently, this bodes well for gold and low yields on treasuries are not at a level where conservative investors yet see them as appealing. However, the Fed is expected to raise rates this year; estimates by Goldman Sachs and JP Morgan indicate four total Fed Fund increases. Higher U.S. rates have the potential to keep the dollar strong, which may limit gold’s upside.

As part of his mining industry report released on January 3rd, Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc. wrote “While a rise in the U.S. dollar and treasury yields are headwinds for gold, we believe investors may view precious metals more favorably in 2022 to protect portfolio values from potential volatility in equity markets, an uncertain path for inflation, and the risk of Federal Reserve monetary policy errors.”

The markets will have more data to evaluate as the U.S. consumer price index and the Fed Beige Book will be released on Wednesday (January 12), and the U.S. producer price index will be released on Thursday.

Take-Away

The year 2022 has already promised dramatic shifts that may include a complete turnaround in the fixed income markets. Since U.S. treasury interest rates are used as a benchmark or “risk-free” return rate against which other investments are judged, financial markets from gold to traditional currencies, digital currencies, real estate, and equities will all be impacted by higher available yields and an increased cost of borrowing.

If inflation continues to outpace interest rates, strength in gold and related assets such as gold mining stocks could continue to do well.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content:

Metals & Mining Fourth Quarter 2021 Review and Outlook

Bond Market Understanding is Again Critical for Stock Investors

C-Suite Interview, Newrange Gold CEO, Bob Archer (Video)

C-Suite Interview Voyager Digital CEO, Stephen Ehrlich (Video)

Sources:

https://www.fxempire.com/forecasts/article/gold-prices-rebound-but-are-capped-by-rising-yields-861339

www.koyfin.com

https://www.investopedia.com/terms/a/accomodativemonetarypolicy.asp

https://www.channelchek.com/news-channel/Industry_Report___Metals_Mining_Fourth_Quarter_2021_Review_and_Outlook

Stay up to date. Follow us:

1-800-FLOWERS.COM, Inc. to Release Results for its Fiscal 2022 Second Quarter on Thursday, January 27, 2022

Posted on January 10, 2022 by Admin

1-800-FLOWERS.COM, Inc. to Release Results for its Fiscal 2022 Second Quarter on Thursday, January 27, 2022

Research, News, and Market Data on 1-800-FLOWERS.COM

JERICHO, N.Y.–(BUSINESS WIRE)– 1-800-FLOWERS.COM, Inc. (NASDAQ: FLWS),a leading provider of gifts designed to help customers express, connect and celebrate, today announced that the Company will release financial results for its fiscal 2022 second quarter (ended 12/26/21) on Thursday, January 27, 2022. The press release will be issued prior to market opening and will be followed by a conference call with members of senior management at 8:00 a.m. (ET).

The conference call will be available via live webcast from the Investor Relations section of the Company’s website at 1800flowersinc.com. A recording of the call will be posted on the website within two hours of the call’s completion. A telephonic replay of the call can be accessed beginning at 2:00 p.m. (ET) on the day of the call through February 3, 2022, (conference call invite says February 2) at: (US) 1-877-344-7529; (
Canada) 855-669-9658; (International) 1-412-317-0088; enter conference ID #:5113256. If you have any questions regarding the above information, please call Patty Altadonna at (516) 237-6113 or the Investor Relations office at (516) 237-6131.

Special Note Regarding Forward-Looking Statements:
Some of the statements contained in the Company’s scheduled Thursday, January 27, 2022, press release and conference call regarding its fiscal 2022 second quarter (ended 12/26/21) results, other than statements of historical fact, may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements. For a more detailed description of these and other risk factors, please refer to the Company’s SEC filings including its Annual Reports and Forms 10K and 10Q available at the Investor Relations section of the Company’s website at 1800flowersinc.com. The Company expressly disclaims any intent or obligation to update any of the forward-looking statements made in the scheduled conference call and any recordings thereof, or in any of its SEC filings, except as may be otherwise stated by the Company.

FLWS-COMP
FLWS-FN

Investor:

Joseph D. Pititto

(516) 237-6131

E-mail: invest@1800flowers.com

Media:

Kathleen Waugh

(516) 237-6028

kwaugh@1800flowers.com

Source: 1-800-FLOWERS.COM, Inc.

2022 Best of

Posted on January 10, 2022 by Admin

Channelchek is the investment community dedicated exclusively to small and micro-cap companies and their industries. Channelchek is the nation’s top free distribution platform dedicated to providing company-sponsored equity research in the small and microcap sectors.

Were now seeking nominations for The 2022 Best Small and Microcap Blog list and also our 2022 Best Vlog for Small and Microcap Investors list. Both are articles that we will publish in March 2022.

As we move into the new year, we’d like to recognize other top-tier content in both the written and video mediums that also benefit the informational needs of small and microcap investors.

The deadline for submissions is February 22, 2022.

Our annual “Best of…” lists seek to identify and honor bloggers and vloggers who have achieved positions of trust and influence among investors interested in companies with market caps below $3b.

Nominations may be submitted using the links below.

Any individual or organization can submit multiple nominations. Nominations may also be submitted confidentially, as indicated on the form.

Channelchek’s editorial team may conduct additional research on nominees and their contributions and followers. We may contact nominators and nominees for more information to support a nomination.

We expect to publish both lists, The 2022 Best Small and Microcap Blog list and also our 2022 Best Vlog for Small and Microcap Investors list, during the month of February 2022.

Make your nomination now.

Blog / Newsletter Nomination

Vlog Nomination

Understanding 5G in Two Minutes

Posted on January 10, 2022 by Admin



	Image Credit: Z z (Pexels)

What is 5G? An Electrical Engineer Explains

5G has been in the news recently as the FAA has asked cellular phone companies to alter their plans to roll out the upgraded communication technology. We’ve all heard the term, and we’re told we should be looking forward to it becoming broadly available. But what is it exactly, and how does it compare to the current 4G most of us now rely on. What follows is a short read that defines 5G and its complexity and capabilities in easy-to-understand language. It was written by Prasenjit Mitra, Professor of Information Sciences and Technology, Penn State.

5G stands for fifth-generation cellular network technology.

It’s the technology that enables wireless communication – for example, from your cellular phone to a cell tower, which channels it to the internet. 5G is a network service provided by telecommunications carriers and is not the same thing as the 5 GHz band on your Wi-Fi router.

5G offers an order of magnitude – 10 times – more bandwidth than its predecessor, 4G. The greater bandwidth is possible because over and above low and medium frequency radio waves, 5G uses additional higher-frequency waves to encode and carry information.

Bandwidth is analogous to the width of a highway. The broader the highway, the more lanes it can have and the more cars it can carry at the same time. This makes 5G much faster and able to handle many more devices.

5G can deliver speeds of around 50 megabits per second, up to more than 1 gigabit per second. A gigabit per second connection allows you to download a high-definition movie in less than a minute. Does this mean no more bad cell connections in crowded places? The increased bandwidth will help, but just as increasing the number of lanes on highways does not always reduce traffic jams, as more people use the expanded highways, 5G is likely to carry a lot more traffic than 4G networks, so you still might not get a good connection sometimes.

In addition to connecting your phone and cellular-enabled laptop, 5G will be connecting many other devices ranging from photo frames to toasters as part of the Internet of Things revolution. So even though 5G can handle up to a million devices per square kilometer, all that bandwidth could be quickly used up and require more – a future 5.5G with even more bandwidth.

Flavors
of 5G

5G can use low-, mid-and high-band frequencies, each with advantages and disadvantages. Lower-frequency waves can travel farther but are slower. Higher-frequency waves travel faster but can go only limited distances. Higher-frequency 5G can achieve gigabit-per-second speeds, which promises to render ethernet and other wired connections obsolete in the future. Currently, however, the higher frequency comes at a higher cost and thus is deployed only where it’s most needed: in crowded urban settings, stadiums, convention centers, airports and concert halls.

A type of 5G service, Ultra-Reliable and Low-Latency Communications can be used where data needs to be transmitted without loss or interruption in service – for example, controlling drones in disaster areas. One day, after the technology is more robust, it could even be used for remote surgery.

Suggested Reading:

The Computer Chip Shortage, Where We Are Now

Can Market Strength Last into 2022?

Can 5G and Airport Safety Coexist?

History Being Made in Net-Zero Passenger Flights

Stay up to date. Follow us:

Release – CoreCivic Awarded New Contract with the State of Arizona at the La Palma Correctional Center

Posted on January 10, 2022 by Admin

CoreCivic Awarded New Contract with the State of Arizona at the La Palma Correctional Center

Research, News, and Market Data on CoreCivic

BRENTWOOD, Tenn., Jan. 10, 2022 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (the Company) announced today that it has been awarded a new contract with the State of Arizona for up to 2,706 adult male inmates on behalf of the Arizona Department of Corrections, Rehabilitation & Reentry (ADCRR) at the Company’s 3,060-bed La Palma Correctional Center in Eloy, Arizona.

The new management contract has an initial term of five years, with one extension option for up to five years thereafter upon mutual agreement. The Company and ADCRR are currently working on a ramp plan that is expected to begin late in the first or early in the second quarter of 2022. Upon full utilization of the new contract the Company expects to generate approximately $75 million to $85 million in annualized revenue.

“We are delighted to have again been selected by the Arizona Department of Corrections, Rehabilitation & Reentry to provide them modern correctional facility capacity and services as they transition away from and close the outdated Arizona State Prison Complex – Florence,” said Damon Hininger, CoreCivic’s President and Chief Executive Officer. “The new contract is the largest prison contract awarded to the private sector by any state in over a decade. However, it is only a small representation of the serious correctional infrastructure challenges facing state and local government around the country and the flexible solutions we can provide.”

The La Palma Correctional Center currently supports the mission of Immigration and Customs Enforcement (ICE) by caring for approximately 1,900 detainees. As the new contract with Arizona commences and state inmates are accepted at the facility, the Company expects to work closely with ICE to transfer their detainee populations to other facilities within the region.

About CoreCivic

CoreCivic is a diversified government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. CoreCivic provides a broad range of solutions to government partners that serve the public good through corrections and detention management, a network of residential reentry centers to help address America’s recidivism crisis, and government real estate solutions. CoreCivic is the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and believes it is the largest private owner of real estate used by government agencies in the U.S. CoreCivic has been a flexible and dependable partner for government for more than 35 years. CoreCivic’s employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good.

Forward-Looking Statements

This press release contains statements as to our beliefs and expectations of the outcome of future events that are “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made. These include, but are not limited to, the risks and uncertainties associated with: (i) changes in government policy (including the United States Department of Justice, or DOJ, not renewing contracts as a result of President Biden’s Executive Order on Reforming Our Incarceration System to Eliminate the Use of Privately Operated Criminal Detention Facilities, or the Private Prison EO) (two agencies of the DOJ, the United States Federal Bureau of Prisons and the United States Marshals Service utilize our services), legislation and regulations that affect utilization of the private sector for corrections, detention, and residential reentry services, in general, or our business, in particular, including, but not limited to, the continued utilization of our correctional and detention facilities by the federal government, and the impact of any changes to immigration reform and sentencing laws (our company does not, under longstanding policy, lobby for or against policies or legislation that would determine the basis for, or duration of, an individual’s incarceration or detention); (ii) our ability to obtain and maintain correctional, detention, and residential reentry facility management contracts because of reasons including, but not limited to, sufficient governmental appropriations, contract compliance, negative publicity and effects of inmate disturbances; (iii) changes in the privatization of the corrections and detention industry, the acceptance of our services, the timing of the opening of new facilities and the commencement of new management contracts (including the extent and pace at which new contracts are utilized), as well as our ability to utilize available beds; (iv) general economic and market conditions, including, but not limited to, the impact governmental budgets can have on our contract renewals and renegotiations, per diem rates, and occupancy; (v) fluctuations in our operating results because of, among other things, changes in occupancy levels, competition, contract renegotiations or terminations, increases in costs of operations, fluctuations in interest rates and risks of operations; (vi) the duration of the federal government’s denial of entry at the United States southern border to asylum-seekers and anyone crossing the southern border without proper documentation or authority in an effort to contain the spread of COVID-19; (vii) government and staff responses to staff or residents testing positive for COVID-19 within public and private correctional, detention and reentry facilities, including the facilities we operate; (viii) restrictions associated with COVID-19 that disrupt the criminal justice system, along with government policies on prosecutions and newly ordered legal restrictions that affect the number of people placed in correctional, detention, and reentry facilities, including those associated with a resurgence of COVID-19; (ix) whether revoking our REIT election, effective January 1, 2021, and our revised capital allocation strategy can be implemented in a cost effective manner that provides the expected benefits, including facilitating our planned debt reduction initiative and planned return of capital to shareholders; (x) our ability to successfully identify and consummate future development and acquisition opportunities and realize projected returns resulting therefrom; (xi) our ability, following our revocation of our REIT election, to identify and initiate service opportunities that were unavailable under the REIT structure; (xii) our ability to have met and maintained qualification for taxation as a REIT for the years we elected REIT status; and (xiii) the availability of debt and equity financing on terms that are favorable to us, or at all. Other factors that could cause operating and financial results to differ are described in the filings we make from time to time with the Securities and Exchange Commission.

CoreCivic takes no responsibility for updating the information contained in this press release following the date hereof to reflect events or circumstances occurring after the date hereof or the occurrence of unanticipated events or for any changes or modifications made to this press release or the information contained herein by any third-parties, including, but not limited to, any wire or internet services.

Contact:

Investors: Cameron Hopewell – Managing Director, Investor Relations – (615) 263-3024
Media: Steve Owen – Vice President, Communications – (615) 263-3107

Why 2022 Investing Will Need to be Different

Posted on January 10, 2022 by Admin



	Image Credit: Marie LaFauci

Is the Tide Turning on Equity Investors?

The Federal Reserve has been accommodating economic growth since at least 2008. A broad stock market bet against the Fed during this 13-year period would have been like trying to swim against the tide. Only in 2018 did the market (S&P 500) have a negative return. The dip that year was in response to fiscal policies, including trade tariffs.

Last week the Fed released minutes from an FOMC meeting held three weeks earlier. These meetings are where Fed governors decide on the stance of monetary policy, making money easier or tighter within the economy. Within the minutes it was clear that the Fed viewed the job market to be near statistically peak levels; they also discussed shrinking their balance sheet. In other words, money that was put into the market to help lower rates and stimulate growth through bond purchases would be unwound by selling securities which has the effect of taking money out of the economy. One reason the market reacted so abruptly is that Fed Chairman Jerome Powell gave a statement to reporters after that meeting, as he normally does, and did not mention this seemingly important change in thought back then.

By the end of last week (January 7), the Nasdaq had fallen 4.5%, the S&P 500 had fallen 1.9%, and the Russell 2000 Small-Cap index by 2.8%. During the Fall of 2020, the Fed chairman presented inflation as not a concern, “transitory” is how he described any pricing strength. Many market watchers at the time saw inflation as more than fleeting and a potential problem. But, not unlike mentioned earlier, going against the Fed can be costly. So, the market did not react to the many forecasts of higher inflation and rates.

Investment Style Shifts

During the period from 2008 until the present, not all sectors or stocks participated in the strong market growth. One only has to look at a comparative chart of the energy sector to realize this. As the Fed begins to step on the economic brakes, there will be sectors and stocks that either benefit from the changed financial situation or have a strong enough product and management team to prosper despite the less accommodative stance of the Fed. Investing in the broader market may be detrimental.

Identifying the sectors poised for growth in a weakened market and the stocks within the sectors that have the greatest opportunity now has increased importance. This may be a dramatic shift for those that have been investing for only a dozen or fewer years. During this time stock fundamentals seemed less important in the selection process than just making sure one was in the market. The truth is fundamental analysis of the various industries and companies within those industries has always been important, it’s just that short-cuts like just climbing aboard an index fund for the ride were easy and rewarding.

Were likely to go through a period where strong economic news is viewed as bad because it could mean a need to accelerate rate hikes, and bad economic news is bad because the Fed isn’t likely to back off even when there are pockets of weakness.

Looking Forward

Very successful investors have been warning against mismatched valuations in indexed funds for a couple of years. These “mismatches” have only broadened since then. Now may be the time for those that believed indexed funds offered diversification to understand that this is less true now than ever before. Also, better understand what you’re buying and the growth potential of individual companies. For example, as of Thursday (January 6), 38% of Nasdaq stocks had fallen 50% or more from their 52-week highs. The benchmark was only down by 5.7% from its all-time high. This is because of the heavy weighting of big tech that remained strong. These stocks mask the underlying weakness of the other companies in the index. Should their massive valuations come more in line with historical norms, they could pull down the index significantly.

Take-Away

The tone of the last Fed meeting, based on the minutes, indicates a more rapid change in direction at the Fed. This has already roiled markets that have been benefitting from years of increasingly accommodative policy. As the tide turns, finding the sectors with the better prospects and the specific stocks within those sectors will require a little more diligence. If you have not already done so, we continue to recommend registering, at no cost, for Channelchek emails; these include research by top-ranked equity analysts and insightful articles on various industries, markets, and economic activity.

Paul Hoffman

Managing Editor, Channelchek

Suggested Reading:

Is the Index Bubble Michael Burry Warned About Still Looming?

Index Funds May Still Fall Apart over Time

Peter Lynch Echoes Michael Burry’s Warning Over Index Fund Investments

Why Michael Burry has Better Opportunity Than Cathie Wood

Sources:

www.koyfin.com

https://www.federalreserve.gov/newsevents/pressreleases/monetary20220105a.htm

https://www.barrons.com/articles/stock-market-tech-stocks-federal-reserve-51641603791

Stay up to date. Follow us:

Release – 1-800-FLOWERS.COM Inc. to Release Results for its Fiscal 2022 Second Quarter

Posted on January 10, 2022 by Admin

1-800-FLOWERS.COM, Inc. to Release Results for its Fiscal 2022 Second Quarter on Thursday, January 27, 2022

Research, News, and Market Data on 1-800-FLOWERS.COM

FLWS-COMP
FLWS-FN

Investor:

Joseph D. Pititto

(516) 237-6131

E-mail: invest@1800flowers.com

Media:

Kathleen Waugh

(516) 237-6028

kwaugh@1800flowers.com

Source: 1-800-FLOWERS.COM, Inc.

Release – COVAXIN BBV152 Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety

Posted on January 10, 2022 by Admin

COVAXIN™ (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety

Research, News, and Market Data on Ocugen

Participants receiving a booster dose six months after second dose of COVAXIN™ saw significant increase (>10-fold across Alpha, Beta, Delta and Delta Plus variants) in neutralizing titers compared to baseline at six months
Persistence of memory B and T cell immune responses at six months post second dose
Pronounced SARS-CoV-2-specific T cell response to COVAXIN™ before and after the booster dose may confer durable and long-term protective efficacy
No serious adverse events such as hospitalizations or deaths were reported
Effectiveness of COVAXIN™ against the Omicron strain is currently being studied and will be reported shortly

MALVERN, Pa., Jan. 08, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced that its partner, Bharat Biotech, posted positive results from a Phase 2 analysis of the vaccine candidate, COVAXIN™ (BBV152), in participants ages 12-64, receiving a booster dose six months following a second dose on the pre-print server, medRxiv. The analysis found that participants receiving a booster dose saw a significant increase in neutralizing titers, an important predictor of vaccine efficacy.

“As the COVID-19 virus continues to evolve, so does our understanding of the efficacy of vaccines and the critical role they play in protecting people from serious disease, hospitalization and death,” said Dr. Shankar Musunuri, Chairman, CEO and Co-Founder, Ocugen, Inc. “These booster data provide critical information about how COVAXIN™ can be used in the ongoing battle against COVID-19. We are encouraged by these results which continue to suggest that COVAXIN™ remains an important, broad-spectrum vaccine candidate with durability.”

Additional data from the analysis found that more than 75 percent of all participants had a detectible neutralizing antibody response six months post their second dose of COVAXIN^™. After receiving the booster, participants also saw an increase in antibody titers (at day 28) that were higher than those achieved after the two-dose primary series. Wild-type neutralizing antibodies (PRNT₅₀) GMTs at one month after a booster dose against Alpha, Beta, Delta and Delta plus variants were increased 10·9, 161·0, 264·7, and 174·2 fold from baseline at six months post second dose, respectively.

“Although protection against severe disease remains high six months following the second dose, a decline in efficacy against symptomatic disease over time and the continued emergence of variants are expected and consistent with what we are seeing with other vaccines. Based on emerging data, a third dose may be beneficial to maintain the highest levels of protection,” said Huma Qamar, MD, MPH, CMI, Associate Vice President, Clinical Development, Ocugen, Inc.

The booster dose analysis also found no serious adverse events, including hospitalization or death, were reported.

About COVAXIN™ (BBV152)
COVAXIN™ (BBV152) is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). COVAXIN™ (BBV152) is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.

With more than 180 million doses having been administered to adults outside the U.S., COVAXIN™ (BBV152) is currently authorized under emergency use in 17 countries, and applications for emergency use authorization are pending in more than 60 other countries. The World Health Organization (WHO) recently added COVAXIN™ (BBV152) to its list of vaccines authorized for emergency use. And, as many as 110 countries have agreed to mutual recognition of Covid-19 vaccination certificates with India that includes vaccination using COVAXIN™ (BBV152). The trade name, COVAXIN™, has not been evaluated by the FDA.

About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets. For more information, please visit www.ocugen.com.

About Bharat Biotech
Bharat Biotech has established an excellent track record of innovation with more than 145 global patents, a wide product portfolio of more than 16 vaccines, 4 bio-therapeutics, registrations in more than 123 countries, and the World Health Organization (WHO) Pre-qualifications. Located in Genome Valley in Hyderabad, India, a hub for the global biotech industry, Bharat Biotech has built a world-class vaccine & bio-therapeutics, research & product development, Bio-Safety Level 3 manufacturing, and vaccine supply and distribution.

Having delivered more than 4 billion doses of vaccines worldwide, Bharat Biotech continues to lead innovation and has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis, Rabies, Chikungunya, Zika, and the world’s first tetanus-toxoid conjugated vaccine for Typhoid. Bharat’s commitment to global social innovation programs and public-private partnerships resulted in introducing path-breaking WHO pre-qualified vaccines BIOPOLIO®, ROTAVAC®, and Typbar TCV® combatting polio, rotavirus, typhoid infections, respectively. The acquisition of the rabies vaccine facility, Chiron Behring, from GlaxoSmithKline (GSK) has positioned Bharat Biotech as the world’s largest rabies vaccine manufacturer. To learn more about Bharat Biotech, visit www.bharatbiotech.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include information about qualitative assessments of available data, potential benefits, expectations for clinical trials, and anticipated timing of clinical trial readouts and regulatory submissions, including statements about data published on the preprint server, medRxiv, by Bharat Biotech, which found that COVAXIN™, when administered as a booster dose, generated a five-fold increase in neutralizing titers, an important predictor of vaccine efficacy, and the potential for this data to support our application to the U.S. Food and Drug Administration (FDA) for emergency use authorization (EUA) of COVAXIN™ in pediatric patients or our planned biologics license application (BLA), assuming the clinical hold is lifted, for approval of COVAXIN™ for use in adult patients, as well as statements regarding the potential short and long-term benefits of receiving a booster dose of COVAXIN™. This information involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates; the risk that we may not resolve the current clinical hold on COVAXIN™ in the near term or at all, or that the FDA could make other decisions that adversely impact our ability to advance the development of COVAXIN™ in the United States, and the implications that this clinical hold may have for our request for EUA of COVAXIN for pediatric use, including the timing and scope of any such authorization; risks associated with preliminary and interim data, including the possibility of unfavorable new clinical trial data and further analyses of existing clinical trial data; the risk that the results of in-vitro studies will not be duplicated in human clinical trials; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from Bharat Biotech’s clinical trials will be published in scientific journal publications and, if so, when and with what modifications; whether the data and results from the preclinical and clinical studies of COVAXIN™, which have been conducted by Bharat Biotech in India, will be accepted by the FDA or otherwise sufficient to support our EUA submission or planned BLA submission, assuming the clinical hold is lifted; the size, scope, timing and outcome of any additional trials or studies that we may be required to conduct to support an EUA or BLA; any additional chemistry, manufacturing, and controls information that we may be required to submit to the FDA; whether and when a BLA for COVAXIN™ will be submitted to or approved by the FDA; whether developments with respect to the COVID-19 pandemic will affect the regulatory pathway available for vaccines in the United States, Canada or other jurisdictions; market demand for COVAXIN™ in the United States or Canada; decisions by the FDA or Health Canada impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of COVAXIN™ in the United States or Canada, including development of products or therapies by other companies. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen Contact:
Ken Inchausti
Head, Investor Relations & Communications
+1 484 237 3398
ken.inchausti@ocugen.com

Please submit investor-related inquiries to: IR@ocugen.com

Release – Indonesia Energy Recognized as Top 3 Performer in 2021

Posted on January 10, 2022 by Admin

Indonesia Energy Recognized as Top 3 Performer in 2021

Research, News, and Market Data on Indonesia Energy

JAKARTA, INDONESIA and DANVILLE, CA / ACCESSWIRE / January 10, 2022 / Indonesia Energy Corporation Limited (NYSE American:INDO) (IEC), an oil and gas exploration and production company focused on Indonesia, today announced that IEC’s operating company has been recognized by the state oil and gas company, Pertamina, as the top three performer in 2021 among 11 oil and gas producing companies in Indonesia under Cooperation Agreement Contracts after comprehensive evaluation on the work commitment, financial, operations and safety records. This recognition is especially significant as IEC just recently announced that daily oil production rate has increased over 50% as a result of the recently completed “Kruh 26” well on its 63,000-acre Kruh Block and IEC plans to commence drilling two back-to-back producing wells at Kruh Block commencing in approximately 60 days. IEC’s production target is to be producing approximately 450 barrels of oil per day after completion of these next two wells. IEC also plans to commence drilling on two additional wells at Kruh Block during the third quarter of 2022.

These new wells are part of IEC’s overall previously announced plan to drill a total of 18 new wells on the Kruh Block over the next 3 years. In order to help meet its drilling plan goals for Kruh Block, IEC is in the process of completing plans to conduct a 30KM seismic program on the Kruh Block which should help to optimize well selection.

Mr. Frank Ingriselli, IEC’s President commented “Indonesia with a more than 100-year history of welcoming international energy companies from around the world, has selected Indonesia Energy Corporation as the 3^rd best energy production company in Indonesia. This recognition highlights our commitment to the highest standards of safety and economic efficiency. There are over 200 oil and gas companies operating in Indonesia and we have risen to the top. We are proud of our entire corporate teams’ dedication and leadership”

About Indonesia Energy Corporation Limited

Indonesia Energy Corporation Limited (NYSE American: INDO) is a publicly traded energy company engaged in the acquisition and development of strategic, high growth energy projects in Indonesia. IEC’s principal assets are its Kruh Block (63,000 acres) located onshore on the Island of Sumatra in Indonesia and its Citarum Block (1,000,000 acres) located onshore on the Island of Java in Indonesia. IEC is headquartered in Jakarta, Indonesia and has a representative office in Danville, California. For more information on IEC, please visit www.indo-energy.com.

Cautionary Statement Regarding Forward-Looking Statements

All statements in this press release of Indonesia Energy Corporation Limited (“IEC”) and its representatives and partners that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Acts”). In particular, when used in the preceding discussion, the words “estimates,” “believes,” “hopes,” “expects,” “intends,” “on-track”, “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Acts, and are subject to the safe harbor created by the Acts. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the IEC’s control, that could cause actual results (including, without limitation, the anticipated results of IEC’s 2020 exploration and production activities and the impact of global oil prices and the novel coronavirus outbreak as described herein) to materially and adversely differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth in the Risk Factors section of the Company’s registration statement and related prospectus for the IEC’s initial public offering filed with the Securities and Exchange Commission (SEC). Copies are of such documents are available on the SEC’s website, www.sec.gov. IEC undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Company Contact:

Frank C. Ingriselli
President, Indonesia Energy Corporation Limited
Frank.Ingriselli@Indo-Energy.com

SOURCE: Indonesia Energy Corporation Limited

Release – PDS Biotech Granted Patent for its Novel HPV16 Immunotherapy

Posted on January 10, 2022 by Admin

PDS Biotech Granted Patent for its Novel HPV16 Immunotherapy

Research, News, and Market Data on PDS Biotech

Extends patent protection of PDS0101 by the United States Patent and Trademark Office Until October 2037

FLORHAM PARK, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune^® T-cell activating technology, today announced that it has been granted U.S. Patent Application No. 15,724,818 titled “Novel HPV16 Non HLA-Restricted T-cell Vaccines, Composition and Methods of Use Thereof” by the United States Patent and Trademark Office (USPTO).

The newly issued patent covers the PDS0101 immunotherapy which consists of a combination of the Versamune technology platform with a unique mixture of short protein fragments derived from the cancer-causing virus, HPV16. The composition promotes the induction of killer (CD8+) T-cells by the immune system that recognize, and attack cancers caused by infection with HPV16 irrespective of the patients’ genetic makeup.

HPV16 is the most oncogenic or cancer-causing type of HPV, and is by far the most prevalent in patients with advanced HPV-associated cancers, including anal, cervical, head and neck, penile, vaginal and vulvar cancers. More than 40,500 patients are diagnosed with HPV16-associated cancers each year according to the International Journal of Cancer. Some of these cancers have been reported to be increasing in incidence over the last few years.

“We remain excited about the promising early efficacy and safety data from our ongoing Phase 2 clinical trials. The early clinical data coupled with the recent grant of the PDS0101 patent that runs into late 2037 puts PDS Biotech in a strong position to progress commercialization of the product to address a significant unmet need for more effective treatment of advanced HPV-associated cancers,” stated Frank Bedu-Addo, Chief Executive Officer of PDS Biotech.

In partnership with Merck & Co., PDS Biotech is evaluating a combination of PDS0101 and KEYTRUDA^® in a Phase 2 study (NCT04260126) in first-line treatment of recurrent or metastatic head and neck cancer, and also in second-line treatment of recurrent or metastatic head and neck cancer in patients who have failed prior checkpoint inhibitor therapy. PDS Biotech is also conducting a Phase 2 clinical study in both second- and third-line treatment of multiple advanced HPV-associated cancers with the National Cancer Institute (NCI). A third Phase 2 clinical trial in first-line treatment of locally advanced cervical cancer is being performed with The University of Texas, MD Anderson Cancer Center.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Company’s proprietary Versamune^® T-cell activating technology platform. Our Versamune^®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune^® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company’s pipeline products address various cancers including HPV16-associated cancers (anal, cervical, head and neck) and breast, colon, lung, prostate and ovarian cancers. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune^®based products; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune^® based products and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Investor Contact:

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: pdsb@cg.capital